CME Review Article:

Therapy of Cutaneous Human
Papillomavirus Infections

by

ALLISON RIVERA MD (1)
&
STEPHEN K. TYRING MD, PhD, MBA (2)

Houston, TX, USA

on August 29, 2005

(1) Department of Dermatology, Baylor College of Medicine, Houston, Texas, USA
(2) Professor of Dermatology, University of Texas Health Science Center, Houston, Texas, USA

References
1. Severson J, Evans TY, Lee P, Chan T, Arany I, Tyring SK. Human Papillomavirus infections: epidemiology, pathogenesis, and therapy. J Cutan Med Surg 2001: 5 : 43–60.
2. Czelusta A, Evans T, Arany I, Tyring S. A guide to immunotherapy of genital warts. Biodrugs 1999: 11
: 319–332.
3. McDonald LL, Stites PC, Buntin DM. Sexually-transmitted diseases update. Dermatol Clin 1997: 15
: 221–232.
4. Centers for Disease Control and Prevention. Sexually Transmitted Disease Guidelines 2002. MMWR Recomm Report 2002: 51 : 1–80.
5. Brown TJ, Yen-Moore A, Tyring SK. An overview of sexuallytransmitted diseases. Part II. J Am Acad Dermatol 1999: 41 661–677, quiz 678–680.
6. Edwards A, Atma-Ram A, Thin RN. Podophyllotoxin 0.5% versus podophyllin 20% to treat penile warts. Genitourin Med 1988: 64 : 263–265.
7. Frazer P, Lacey C. Podophyllotoxin is superior to podophyllin in the treatment of genital warts. J Eur Acad Venereol 1993: 2 : 328–334.
8. Jablonska S. Traditional therapies for the treatment of condylomata acuminata (genital warts). Australas J Dermatol 1998: 39 (Suppl. 1): S2–S4.
9. Kinghorn GR, McMillan A, Mulcahy F, Drake S, Lacey C, Bingham JS. An open, comparative, study of the efficacy of 0.5% podophyllotoxin lotion and 25% podophyllotoxin solution in the treatment of condylomata acuminata in males and females. Int J STD AIDS 1993: 4 : 194–199.
10. Syed TA, Cheema KM, Khayyami M, Ahmad SA, Ahmad SH, Ahmad S. Human leukocyte interferon-alpha versus podophyllotoxin in cream for the treatment of genital warts in males. A placebo-controlled, double-blind, comparative study. Dermatology 1995: 191 : 129–132.
11. Godley MJ, Bradbeer CS, Gellan M, Thin RN. Cryotherapy compared with trichloroacetic acid in treating genital warts. Genitourin Med 1987: 63 : 390–392.
12. Krebs HB. The use of topical 5-fluorouracil in the treatment of genital condylomas. Obstet Gynecol Clin North Am 1987: 14 : 559–568.
13. Pride GL. Treatment of large lower genital tract condylomata acuminata with topical 5-fluorouracil. J Reprod Med 1990: 35 : 384–387.
14. Ferenczy A. Comparison of 5-fluorouracil and CO 2 laser for treatment of vaginal condylomata. Obstet Gynecol 1984: 64 : 773–778.
15. Goodman A, Zukerberg LR, Nikrui N, Scully RE. Vaginal adenosis and clear cell carcinoma after 5-fluorouracil treatment for condylomas. Cancer 1991: 68 : 1628–1632.
16. Swinehart JM, Skinner RB, McCarty JM et al. Development of intralesional therapy with fluorouracil/adrenaline injectable gel for management of condylomata acuminata: two phase II clinical studies. Genitourin Med 1997: 73 481–487.
17. Swinehart JM, Sperling M, Phillips S et al. Intralesional fluorouracil/epinephrine injectable gel for treatment of condylomata acuminata. A phase 3 clinical study. Arch Dermatol 1997: 133 : 67–73.
18. Shelley WB, Shelley ED. Intralesional bleomycin sulfate therapy for warts. A novel bifurcated needle puncture technique. Arch Dermatol 1991: 127 : 234–236.
19. Munn SE, Higgins E, Marshall M, Clement M. A new method of intralesional bleomycin therapy in the treatment of recalcitrant warts. Br J Dermatol 1996: 135 : 969– 971.
20. Miller RA. Nail dystrophy following intralesional injections of bleomycin for a periungual wart. Arch Dermatol 1984: 120 : 963–964.
21. Menter A, Black-Noller G, Riendeau LA, Monti KL. The use of EMLA cream and 1% lidocaine infiltration in men for relief of pain associated with the removal of genital warts by cryotherapy. J Am Acad Dermatol 1997: 37 : 96–100.
22. Ferenczy A, Bergeron C, Richart RM. Human Papillomavirus DNA in CO2 laser-generated plume of smoke and its consequences to the surgeon. Obstet Gynecol 1990: 75 : 114–118.
23. Ferenczy A, Bergeron C, Richart RM. Carbon dioxide laser energy disperses human Papillomavirus
deoxyribonucleic acid onto treatment fields. Am J Obstet Gynecol 1990: 163 1271–1274.
24. Gloster HM Jr, Roenigk RK. Risk of acquiring human Papillomavirus from the plume produced by the carbon dioxide laser in the treatment of warts. J Am Acad Dermatol 1995: 32 : 436–441.
25. Hughes PS, Hughes AP. Absence of human Papillomavirus DNA in the plume of erbium: YAG laser-treated warts. J Am Acad Dermatol 1998: 38 : 426–428.
26. Bergman A, Nalick R. Genital human Papillomavirus infection in men. Diagnosis and treatment with a laser and 5-fluorouracil. J Reprod Med 1991: 36 : 363–366.
27. Ferenczy A. Laser treatment of genital human Papillomavirus infections in the male patient. Obstet Gynecol Clin North Am 1991: 18 : 525–535.
28. von Krogh G. Management of anogenital warts (condylomata acuminata). Eur J Dermatol 2001: 11
: 598–603; quiz 604.
29. Bornstein J, Pascal B, Zarfati D, Goldshmid N, Abramovici H. Recombinant human interferon-beta for condylomata acuminata: a randomized, double-blind, placebo-controlled study of intralesional therapy. Int J STD AIDS 1997: 8 : 614– 621.
30. Eron LJ, Judson F, Tucker S et al. Interferon therapy for condylomata acuminata. N Engl J Med 1986:
315 : 1059– 1064.
31. Friedman-Kien A. Management of condylomata acuminata with Alferon N injection, interferon alfa-n3 (human leukocyte derived). Am J Obstet Gynecol 1995: 172 : 1359–1368.
32. Friedman-Kien AE, Eron LJ, Conant M et al. Natural interferon alfa for treatment of condylomata acuminata. Jama 1988: 259 : 533–538.
33. Monsonego J, Cessot G, Ince SE, Galazka AR, Abdul-Ahad AK. Randomized double-blind trial of recombinant interferonbeta for condyloma acuminatum. Genitourin Med 1996: 72 : 111–114.
34. Reichman RC, Micha JP, Weck PK et al. Interferon alpha-n1 (Wellferon) for refractory genital warts: efficacy and tolerance of low dose systemic therapy. Antiviral Res 1988: 10 41–57.
35. Vance JC, Bart BJ, Hansen RC et al. Intralesional recombinant alpha-2 interferon for the treatment of patients with condyloma acuminatum or verruca plantaris. Arch Dermatol 1986: 122 : 272–277.
36. Welander CE, Homesley HD, Smiles KA, Peets EA. Intralesional interferon alpha-2b for the treatment of genital warts. Am J Obstet Gynecol 1990: 162 : 348–354.
37. Eedy DJ. Imiquimod: a potential role in dermatology? Br J Dermatol 2002: 147 : 1– 6.
38. Hemmi H, Kaisho T, Takeuchi O et al. Small antiviral compounds activate immune cells via the TLR7 MyD88- dependent signaling pathway. Nat Immunol 2002: 3 :196– 200.
39. Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol 1999: 21 : 1–14.
40. Kono T, Kondo S, Pastore S et al. Effects of a novel topical immunomodulator, imiquimod, on keratinocyte cytokine gene expression. Lymphokine Cytokine Res 1994:13: 71– 76.
41. Hengge UR, Cusini M. Topical immunomodulators for the treatment of external genital warts, cutaneous warts and molluscum contagiosum. Br J Dermatol 2003: 149 (Suppl 66): 15–19.
42. Garland SM, Sellors JW, Wikstrom A et al. Imiquimod 5% cream is a safe and effective self-applied treatment for anogenital warts – results of an open-label, multicentre Phase IIIB trial. Int J STD AIDS 2001:
12 : 722–729.
43. Edwards L, Ferenczy A, Eron L et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group Human Papillomavirus Arch Dermatol 1998: 134 : 25–30.
44. Beutner KR, Spruance SL, Hougham AJ, Fox TL, Owens ML, Douglas JM Jr. Treatment of genital warts with an immuneresponse modifier (imiquimod). J Am Acad Dermatol 1998: 38 : 230–239.
45. Beutner KR, Tyring SK, Trofatter KF Jr et al. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother 1998: 42 : 789–794.
46. Edwards L. Imiquimod in clinical practice. Australas J Dermatol 1998: 39 (Suppl. 1): S14–S16.
47. Gilson RJ, Shupack JL, Friedman-Kien AE et al. A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. Imiquimod Study Group Aids 1999: 13
: 2397–2404.
48. Goldstein D, Hertzog P, Tomkinson E et al. Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification. J Infect Dis 1998: 178 : 858–861.
49. Snoeck R, Andrei G, De Clercq E. Cidofovir in the treatment of HPV-associated lesions. Verh K Acad Geneeskd Belg 2001: 63 : 93–120, discussion 120–122.
50. Tyring S, Douglas J, Corey L. A phase I/II study of cidofovir gel for refractory condyloma acuminatum in patients with HIV infection (poster 296). 55th Annual Meeting of Dermatology. San Francisco, CA, 1997.
51. Snoeck R, Bossens M, Parent D et al. Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human Papillomavirus infection. Clin Infect Dis 2001: 33 : 597–602.
52. Zabawski EJ Jr, Cockerell CJ. Topical and intralesional cidofovir: a review of pharmacology and therapeutic effects. J Am Acad Dermatol 1998: 39 : 741–745.
53. Snoeck R, Noel JC, Muller C, De Clercq E, Bossens M. Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III). J Med Virol 2000: 60 : 205–209.
54. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of human Papillomavirus type 16 vaccine. N Engl J Med 2002: 347 : 1645–1651.
55. Fife KH. Human Papillomavirus vaccine development. Australas J Dermatol 1998: 39 (Suppl. 1): S8–S10.

Back to article